Anita Kohli

8.0k total citations · 3 hit papers
77 papers, 2.2k citations indexed

About

Anita Kohli is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Anita Kohli has authored 77 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Hepatology, 43 papers in Epidemiology and 12 papers in Infectious Diseases. Recurrent topics in Anita Kohli's work include Hepatitis C virus research (38 papers), Liver Disease Diagnosis and Treatment (33 papers) and Hepatitis B Virus Studies (17 papers). Anita Kohli is often cited by papers focused on Hepatitis C virus research (38 papers), Liver Disease Diagnosis and Treatment (33 papers) and Hepatitis B Virus Studies (17 papers). Anita Kohli collaborates with scholars based in United States, United Kingdom and Nigeria. Anita Kohli's co-authors include Shyam Kottilil, Amy C Sherman, Ashton A. Shaffer, Henry Masur, Anu Osinusi, Amy Nelson, Stephen A. Harrison, Sreetha Sidharthan, Nadege Gunn and Zayani Sims and has published in prestigious journals such as JAMA, Nature Communications and Annals of Internal Medicine.

In The Last Decade

Anita Kohli

75 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of Hepatitis C

2014 334 citations Anita Kohli, Ashton A. Shaffer et al. profile →
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

2020 218 citations Stephen A. Harrison, Guy Neff et al. Gastroenterology profile →
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

2022 157 citations Naim Alkhouri, Robert Herring et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anita Kohli United States	24	1.5k	1.2k	319	304	249	77	2.2k
Tatsuya Ide Japan	20	2.2k 1.5×	2.2k 1.8×	168 0.5×	174 0.6×	301 1.2×	120	2.9k
Chung‐Feng Huang Taiwan	28	2.3k 1.6×	2.3k 1.9×	223 0.7×	171 0.6×	256 1.0×	204	3.2k
David Sheridan United Kingdom	15	2.3k 1.5×	2.2k 1.8×	315 1.0×	145 0.5×	182 0.7×	36	2.9k
Guillaume Pénaranda France	28	1.5k 1.1×	1.6k 1.3×	212 0.7×	298 1.0×	154 0.6×	120	2.7k
Yoshihiko Yano Japan	23	1.0k 0.7×	897 0.8×	155 0.5×	135 0.4×	204 0.8×	152	1.7k
Hélène Fontaine France	23	3.2k 2.2×	3.0k 2.5×	165 0.5×	339 1.1×	312 1.3×	58	3.9k
John Koskinas Greece	32	2.0k 1.3×	2.1k 1.8×	152 0.5×	232 0.8×	417 1.7×	140	3.5k
Ramazan Idılman Türkiye	32	3.1k 2.1×	2.8k 2.3×	252 0.8×	218 0.7×	323 1.3×	176	4.0k
Anuchit Chutaputti Thailand	16	2.2k 1.5×	2.0k 1.6×	125 0.4×	127 0.4×	188 0.8×	30	2.6k
Kiyoaki Ito Japan	27	1.9k 1.3×	1.5k 1.2×	155 0.5×	204 0.7×	439 1.8×	170	2.8k

Countries citing papers authored by Anita Kohli

Since Specialization

Citations

This map shows the geographic impact of Anita Kohli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anita Kohli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anita Kohli more than expected).

Fields of papers citing papers by Anita Kohli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anita Kohli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anita Kohli. The network helps show where Anita Kohli may publish in the future.

Co-authorship network of co-authors of Anita Kohli

This figure shows the co-authorship network connecting the top 25 collaborators of Anita Kohli. A scholar is included among the top collaborators of Anita Kohli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anita Kohli. Anita Kohli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Agostini, Maria L., Gretja Schnell, Julia di Iulio, et al.. (2024). Resistance analysis in the phase III COMET-TAIL study: treatment of COVID-19 with intramuscular or intravenous sotrovimab. Future Virology. 19(5). 185–198.

Noureddin, Mazen, Edward Mena, Raj Vuppalanchi, et al.. (2023). Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores. Hepatology Communications. 7(5). 24 indexed citations

Alkhouri, Naim, Robert Herring, Heidi Kabler, et al.. (2022). Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. Journal of Hepatology. 77(3). 607–618. 157 indexed citations breakdown →

Younossi, Zobair M., Maria Stepanova, Mazen Noureddin, et al.. (2021). Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. Hepatology Communications. 5(7). 1201–1211. 24 indexed citations

Harrison, Stephen A., Seth J. Baum, Nadege Gunn, et al.. (2021). Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease. The American Journal of Gastroenterology. 116(12). 2399–2409. 18 indexed citations

Avery, Robert A., J. Clay Bavinger, Maxwell Pistilli, et al.. (2021). The sensitivity and specificity of retinal and choroidal folds to distinguish between mild papilloedema and pseudopapilledema. Eye. 35(11). 3131–3136. 6 indexed citations

Pistilli, Maxwell, Anita Kohli, Grant T. Liu, et al.. (2020). Utility of Spectral-Domain Optical Coherence Tomography in Differentiating Papilledema From Pseudopapilledema: A Prospective Longitudinal Study. Journal of Neuro-Ophthalmology. 41(4). e509–e515. 10 indexed citations

Harrison, Stephen A., Guy Neff, Cynthia D. Guy, et al.. (2020). Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. Gastroenterology. 160(1). 219–231.e1. 218 indexed citations breakdown →

Shrivastava, Shikha, Sara Romani, Rebecca Lee, et al.. (2018). Multitarget Direct‐Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus. Hepatology Communications. 2(12). 1451–1466. 19 indexed citations

10.

Thornton, Karla, Paulina Deming, Richard Manch, et al.. (2016). Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment. Hepatology International. 10(4). 624–631. 8 indexed citations

11.

Kohli, Anita, et al.. (2016). Alcoholic Liver Disease. Clinics in Liver Disease. 20(3). 563–580. 40 indexed citations

12.

Boroń, Alicja, et al.. (2016). The Prevalence of Non-Alcoholic Steatohepatitis among Diabetic Patients Followed by Primary Care and Endocrinology. Journal of Hepatology. 64(2). S486–S486. 1 indexed citations

13.

Townsend, Kerry, Eric G. Meissner, Sreetha Sidharthan, et al.. (2015). Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. AIDS Research and Human Retroviruses. 32(5). 456–462. 28 indexed citations

14.

Petersen, Tess, Kerry Townsend, Sreetha Sidharthan, et al.. (2015). High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatology International. 10(2). 310–319. 50 indexed citations

15.

Shaffer, Ashton A., Jon Hubbard, Kerry Townsend, et al.. (2014). Short Communication: Serum-Based Assay Accurately Detects Single Nucleotide Polymorphisms of IL28B and SOCS3 in HIV/Hepatitis C Virus-Coinfected Subjects. AIDS Research and Human Retroviruses. 30(8). 792–795. 3 indexed citations

16.

Osinusi, Anu, Anita Kohli, Amy Nelson, et al.. (2014). Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse. Annals of Internal Medicine. 161(9). 634–638. 58 indexed citations

17.

Funk, Emily K., Ashton A. Shaffer, Bhavana Shivakumar, et al.. (2013). Short Communication: Interferon/Ribavirin Treatment for HCV Is Associated with the Development of Hypophosphatemia in HIV/Hepatitis C Virus-Coinfected Patients. AIDS Research and Human Retroviruses. 29(9). 1190–1194. 7 indexed citations

18.

Barrett, Lisa Feldman, Anu Osinusi, Anita Kohli, et al.. (2013). 1 ALTERED HCV SPECIFIC T CELL IMMUNITY VERY EARLY IN INTERFERON FREE HCV DAA THERAPY. Journal of Hepatology. 58. S1–S1. 13 indexed citations

19.

Sherman, Amy C, Nirupama Trehanpati, Marybeth Daucher, et al.. (2012). Augmentation of Hepatitis B Virus-Specific Cellular Immunity with Programmed Death Receptor-1/Programmed Death Receptor-L1 Blockade in Hepatitis B Virus and HIV/Hepatitis B Virus Coinfected Patients Treated with Adefovir. AIDS Research and Human Retroviruses. 29(4). 665–672. 27 indexed citations

20.

Kohli, Anita, et al.. (1997). Intrathoracic gastric volvulus--acute and chronic presentation.. PubMed. 95(9). 522–3. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact